ACVR1 and fibrodysplasia ossificans progressiva: Palovarotene was approved firstly by the Food and Drug Administration to treat FOP [49], and other four drugs are in trials, including BLU-782 (IPN60130), a ALK2 R206H inhibitor, which could prevent HO in FOP [50].